





NOW FOR ARIMIDEX—

THE ARIMIDEX PACK

COMING TO PHARMACIES IN JUNE!



Tablets not actual size



Dear Pharmacist:

AstraZeneca is pleased to announce that starting June 2, 2008, ARIMIDEX will be available in a calendar blister pack called the ARIMIDEX PACK. The ARIMIDEX PACK is designed to be a useful tool to help remind patients to take their medication every day, and to help you when talking to patients about the importance of adherence. Patients will receive the same tablet and dose of ARIMIDEX as before, but in a more convenient calendar blister pack. The two tablets marked FINAL Tablet should be taken, one each day for the last two days of this 30 day pack. The final tablets help to remind patients it's time to refill their prescription. As of June 2, 2008, AstraZeneca

will be dispensing ARIMIDEX only in the ARIMIDEX PACK utilizing the new NDC number (00310-0201-37). However, due to varying stock levels and supply chain variability, it may take time for the supply chain to fully transition to the ARIMIDEX PACK. Please continue to utilize the current 30-tablet-count bottles of ARIMIDEX until that inventory has been exhausted!

Returns of these products will be subject to the AstraZeneca Expired Return Goods Policy. Under the policy, in order to be eligible for return, product must be within six (6) months of expiration and not out of date by more than one (1) year. The policy provides for reimbursement at current wholesale acquisition cost (WAC) less five percent (5%) of the merchandise returned, unless otherwise required by applicable law.

ARIMIDEX is an aromatase inhibitor (AI) indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. The ATAC* trial demonstrated that ARIMIDEX was superior to tamoxifen in prolonging disease-free survival. The most recent analysis of ATAC included 5 years of therapy and 3+ years of follow-up. To review the findings or get a copy of the reprint of the 100-month update to the ATAC trial, visit www.atac100-us.com.

AstraZeneca offers patient support programs as a tool to help you encourage patients to remain adherent. AZ CSN provides product information as well as benefit verification and financial assistance for AstraZeneca medicines. For any information, questions, or comments about ARIMIDEX, contact AZCSN at 1-866-992-9276 Monday through Friday, 8 AM to 7 PM EST.

Important Information About ARIMIDEX

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Important Safety Information About ARIMIDEX

ARIMIDEX is only for postmenopausal women. ARIMIDEX can cause fetal harm when administered to a pregnant woman. Before starting treatment with ARIMIDEX, pregnancy must be excluded (see WARNINGS section of full Prescribing Information).

Common side effects seen with ARIMIDEX vs tamoxifen in the early breast cancer trial after 5 years of treatment include hot flashes (36% vs 41%), joint disorders (including arthritis, arthrosis, arthralgia) (36% vs 29%), asthenia (19% vs 18%), mood disturbances (19% vs 18%), pain (17% vs 16%), pharyngitis (14% vs 14%), nausea and vomiting (13% vs 12%), depression (13% vs 12%), hypertension (13% vs 11%), osteoporosis (11% vs 7%), peripheral edema (10% vs 11%), and headache (10% vs 8%). Fractures, including fractures of the spine, hip, and wrist, occurred more often with ARIMIDEX vs tamoxifen (10% vs 7%).


Compared to baseline, ARIMIDEX showed a mean decrease in both lumbar spine and total hip bone mineral density. Tamoxifen showed a mean increase in these measurements. Nine percent of patients receiving ARIMIDEX had an elevated serum cholesterol vs 3.5% of patients receiving tamoxifen.

Clinical and pharmacokinetic results suggest that tamoxifen should not be administered with ARIMIDEX. Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.

Please see accompanying full Prescribing Information

*ARIMIDEX, Tamoxifen, Alone or in Combination

ARIMIDEX is a registered trademark of the AstraZeneca group of companies.
©2008 AstraZeneca Pharmaceuticals LP. All rights reserved. 5/08 262237



Arimidex[®]
anastrozole 1mg
tablets

The power to help protect

AstraZeneca